We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+10.27%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$22.8B
AUM Growth
-$510M
Cap. Flow
-$2.26B
Cap. Flow %
-9.9%
Top 10 Hldgs %
40.08%
Holding
187
New
21
Increased
43
Reduced
39
Closed
22

Top Buys

Rank Stock Value
1
DIS icon
Walt Disney
DIS
+$207M
2
ANSS
Ansys
ANSS
+$201M
3
WWD icon
Woodward
WWD
+$192M
4
SWN
Southwestern Energy Company
SWN
+$168M
5
SQSP
Squarespace, Inc.
SQSP
+$130M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$294M
2
NDAQ icon
Nasdaq
NDAQ
+$256M
3
CRM icon
Salesforce
CRM
+$231M
4
AZN icon
AstraZeneca
AZN
+$188M
5
ARMK icon
Aramark
ARMK
+$187M

Sector Composition

Rank Sector Weight
1 Healthcare 31.84%
2 Technology 13.48%
3 Financials 9.84%
4 Communication Services 6.79%
5 Industrials 6.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVCPW
151
DELISTED
Swiftmerge Acquisition Corp. Warrants
IVCPW
$71.8K ﹤0.01%
990,000
– –
IRWD icon
152
Ironwood Pharmaceuticals
IRWD
$709M
$53.6K ﹤0.01%
13,000
– –
LU icon
153
Lufax Holding
LU
$1.2B
$52.4K ﹤0.01%
15,000
– –
SLDPW icon
154
Solid Power Inc Warrant
SLDPW
$6.93M
$48.6K ﹤0.01%
405,316
– –
GATEW
155
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$48.3K ﹤0.01%
1,485,000
– –
CITEW
156
DELISTED
Cartica Acquisition Corp Warrant
CITEW
$28K ﹤0.01%
175,000
– –
RVMDW icon
157
Revolution Medicines Inc Warrant
RVMDW
$130M
$16.8K ﹤0.01%
120,085
– –
RCFA.WS
158
DELISTED
RCF Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
RCFA.WS
$15.1K ﹤0.01%
300,000
– –
GHIXW
159
DELISTED
Gores Holdings IX, Inc. Warrant
GHIXW
$14.6K ﹤0.01%
166,664
– –
NVNIW
160
Nvni Group Limited Warrants
NVNIW
$7.72K ﹤0.01%
375,000
– –
JWSM.WS
161
DELISTED
Jaws Mustang Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
JWSM.WS
$6.5K ﹤0.01%
200,000
– –
BCSAW
162
DELISTED
Blockchain Coinvestors Acquisition Corp. I Warrant
BCSAW
$3K ﹤0.01%
150,000
– –
RGTIW icon
163
Rigetti Computing Warrants
RGTIW
$178M
$2.08K ﹤0.01%
22,675
– –
APLS
164
DELISTED
Apellis Pharmaceuticals
APLS
– –
-6,000
Closed -$230K
AZN icon
165
AstraZeneca
AZN
$257B
– –
-1,204,859
Closed -$188M
CRSP icon
166
CRISPR Therapeutics
CRSP
$5.75B
– –
-530,000
Closed -$28.6M
HUM icon
167
Humana
HUM
$45.5B
– –
-600
Closed -$224K
IONS icon
168
Ionis Pharmaceuticals
IONS
$9.93B
– –
-4,800
Closed -$229K
MRUS
169
DELISTED
Merus
MRUS
– –
-4,000
Closed -$237K
NRIX icon
170
Nurix Therapeutics
NRIX
$2.77B
– –
-108,799
Closed -$2.27M
PCG icon
171
PG&E
PCG
$38.8B
– –
-692,323
Closed -$12.1M
QTRX icon
172
Quanterix
QTRX
$141M
– –
-80,000
Closed -$1.06M
RIO icon
173
Rio Tinto
RIO
$171B
– –
-137,500
Closed -$9.07M
SRPT icon
174
CALL
Sarepta Therapeutics
SRPT
$1.98B
– –
-133,300
Closed -$21.1M
SYRE icon
175
Spyre Therapeutics
SYRE
$9.39B
– –
-666,000
Closed -$15.7M
4 5 6
7
8

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2024 Portfolio in Review

As of Q3 2024, Thomas Steyer held 187 positions worth $22.8B, down 2.2% from $23.3B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Thomas Steyer withdrew a net $2.26B in Q3 2024, closing 22 positions and reducing 39 holdings. Its most notable exit was AstraZeneca, an estimated $188M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 29% a quarter earlier, followed by Technology and Financials.

Against the trend, Thomas Steyer opened a new position in Woodward worth $198M.

  • Thomas Steyer's largest Q3 2024 buy was Woodward: 1,154,000 shares worth $198M.
  • Thomas Steyer added most to Walt Disney in Q3 2024, an estimated $207M increase.
  • Thomas Steyer's biggest Q3 2024 reduction was UnitedHealth, cutting an estimated $294M.
  • Thomas Steyer fully exited AstraZeneca in Q3 2024, selling an estimated $188M.
  • Thomas Steyer's ten largest holdings make up 40% of its $22.8B portfolio in Q3 2024.
  • Thomas Steyer opened 21 new positions and closed 22 in Q3 2024.
  • Thomas Steyer's portfolio value fell 2.2% quarter-over-quarter to $22.8B.

Based on Farallon Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.